PEG-MGF (PEGylated Mechano Growth Factor) is a synthetic form of the IGF-1 Ec splice variant peptide conjugated to polyethylene glycol to extend its circulating half-life. Non-PEGylated MGF has a plasma half-life estimated at minutes due to rapid proteolytic degradation[1]. PEGylation extends the half-life to hours in animal models by reducing enzymatic cleavage and renal filtration. No published human pharmacokinetic study exists for PEG-MGF. Data quality: Animal Study — no human PK data has been published as of May 2026.
| Parameter | Value | Source |
|---|---|---|
| Half-Life — Non-PEGylated MGF | Minutes (estimated) | Yang SY & Goldspink G 2002 [1] |
| Half-Life — PEG-MGF | Hours (animal data; human unknown) | PEGylation pharmacology; animal models |
| Time to Peak (Tmax) | Not published in humans | — |
| Route(s) of Administration | Subcutaneous injection, Intramuscular injection | — |
| Full Clearance (5 half-lives) | Not established in humans | — |
| Standard Research Protocol | 200–400 mcg SC/IM 1–2× weekly (community) | Community protocol (no clinical trial basis) |
| Data Quality | Animal Study — No published human PK data exists as of May 2026 | — |
PEG-MGF's half-life in humans has not been formally established in any published pharmacokinetic study. The available data comes from two sources: characterization of non-PEGylated MGF's rapid degradation, and general PEGylation pharmacology principles applied in animal models[1].
Non-PEGylated MGF (the Ec peptide of the IGF-1 splice variant) was characterized by Yang SY and Goldspink G in a 2002 FEBS Letters study (PMID 12413444)[1] that identified the mechano growth factor splice variant and demonstrated its rapid degradation when administered exogenously. The non-PEGylated peptide is estimated to have a half-life of minutes — too short for practical injectable use. PEGylation was developed specifically to address this limitation by attaching polyethylene glycol chains that physically shield the peptide from protease attack and increase molecular weight to reduce renal filtration.
PEGylation is a well-established pharmaceutical technology used to extend peptide and protein half-lives. By attaching PEG polymer chains to the peptide, the conjugate becomes: (1) larger — reducing renal filtration below the glomerular filtration threshold; (2) more hydrophilic — altering distribution; and (3) sterically shielded from protease recognition. These effects collectively extend half-life from minutes (non-PEGylated MGF) to hours (PEG-MGF, based on animal model data). The same technology is used in approved drugs including peginterferon and pegfilgrastim, where PEGylation extends half-lives from minutes to days for larger proteins.
PEG-MGF's biological mechanism involves activation of IGF-1 receptors on muscle satellite cells, triggering proliferation and differentiation. IGF-1 receptor signaling cascades (PI3K-Akt, MAPK/ERK) initiate transcriptional programs that can persist beyond the peptide's plasma presence. The precise relationship between PEG-MGF's plasma half-life and its biological effect duration has not been characterized in humans, and the lack of human PK data makes any specific claim about this distinction in humans speculative.
Because no human pharmacokinetic study exists for PEG-MGF, a precise clearance timeline cannot be stated. Based on PEGylation pharmacology in animal models, the following table is illustrative — it should not be interpreted as established human data:
| Half-Lives Elapsed | Estimated Time (Animal Model Basis) | % Remaining |
|---|---|---|
| 1 | Several hours (estimate; not human-confirmed) | 50% |
| 2 | Double above | 25% |
| 3 | Triple above | 12.5% |
| 4 | Quadruple above | 6.25% |
| 5 (clearance threshold) | Not established in humans | ~3% |
The community protocols for PEG-MGF (typically 200–400 mcg SC or IM administered once or twice weekly) are based on the assumption that PEGylation has extended the half-life from minutes to hours — allowing weekly administration to produce meaningful receptor engagement. This is pharmacokinetically rational given PEGylation's known effects on peptide stability, but it is not supported by human clinical trial data. No clinical trial has established an optimal dose, frequency, or duration for PEG-MGF in humans.
| Compound | Half-Life | Data Quality | Mechanism |
|---|---|---|---|
| PEG-MGF | Hours (animal est.) | Animal Study | IGF-1R / muscle satellite cells |
| MGF (non-PEGylated) | Minutes (est.) | Animal/structural est. | IGF-1R / muscle satellite cells |
| IGF-1 LR3 | ~20–30 hours | Animal Study | IGF-1R; reduced IGFBP binding |
| IGF-1 (native) | ~10–20 min (free) | Human PK data | IGF-1R; high IGFBP binding |
| Route | Half-Life | Bioavailability | Tmax | Notes |
|---|---|---|---|---|
| Subcutaneous | Hours (animal est.) | Not published | Not published | Most common research protocol route |
| Intramuscular | No published data | No published data | No published data | Used in some protocols for local myogenic targeting |
| Intravenous | No published data | 100% | Minutes | Not used in research protocols |
| Oral | Not viable | Negligible | — | GI proteolysis prevents meaningful systemic absorption |
PEG-MGF is not included in standard WADA anti-doping panels or standard workplace drug tests. As a research peptide with no clinical approval, it is not a target of routine testing programs. Standard immunoassay panels do not detect peptides at the concentrations and molecular specificity required.
No published forensic or anti-doping detection study has specifically characterized the urinary detection window for PEG-MGF. WADA's monitoring program includes some IGF-1-related peptides, and IGF-related assays could in principle detect PEG-MGF or its metabolic products. However, no published detection method specifically targeting PEG-MGF has been identified in the literature as of May 2026. The PEG conjugate may also complicate detection by altering the mass spectrum compared to non-PEGylated peptide fragments.
MGF is the C-terminal Ec peptide domain of the IGF-1 Ec splice variant — a 24-amino-acid fragment generated endogenously in muscle in response to mechanical strain. When produced endogenously, MGF acts locally in a paracrine/autocrine manner, signaling to nearby muscle satellite cells to initiate proliferation and myogenesis. The peptide's endogenous role is transient: it is meant to signal acutely following injury, not to maintain sustained systemic concentrations[1].
When administered exogenously as an unmodified peptide, this short-duration design becomes a pharmacokinetic problem: serum peptidases rapidly cleave the small unprotected peptide, and its low molecular weight makes it subject to renal filtration. The result is a plasma half-life estimated at minutes — insufficient for a subcutaneous injection to maintain detectable systemic concentrations for any meaningful duration[1].
PEGylation addresses this limitation by attaching branched or linear polyethylene glycol chains to the peptide. PEG chains are hydrophilic, flexible polymers that create a steric shield around the peptide, reducing protease access and increasing effective molecular weight above the renal filtration threshold. This mechanism — validated in multiple approved biologic drugs — extends the MGF half-life from minutes to hours in animal models[1]. The specific magnitude of half-life extension for PEG-MGF depends on PEG chain length, branching, and attachment site — variables that differ between PEG-MGF preparations available in research markets and are not uniformly characterized.
Log injection timing, dose, and protocol notes on-device. No account required. Free iOS app.
Download on App StoreThe Halflife app tracks PEG-MGF alongside 44 other compounds — all with citation-backed PK data. Free on iOS.
Download on the App Store